Vpx complementation of 'non-macrophage tropic' R5 viruses reveals robust entry of infectious HIV-1 cores into macrophages

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Mlcochova, Petra ^a   Watters, Sarah A ^a   Towers, Greg J ^a   Noursadeghi, Mahdad ^a   Gupta, Ravindra K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Entry; HIV; Macrophages; Reverse transcription; Transmitted founder viruses; Vpx

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAG PROTEIN; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VPX PROTEIN;

ARTICLE; CONTROLLED STUDY; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN R5); MACROPHAGE; NONHUMAN; PSEUDOTYPING; REVERSE TRANSCRIPTION; VIRUS CORE; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS TRANSMISSION;

CELL LINE; HIV-1; HUMANS; MACROPHAGES; RECEPTORS, CCR5; RECEPTORS, HIV; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRAL TROPISM; VIRUS INTERNALIZATION;

EID: 84899097258     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-11-25     Document Type: Article

References (57)

1. Koppensteiner H, Brack-Werner R, Schindler M. Macrophages and their relevance in human immunodeficiency virus type I infection. Retrovirology 2012, 9:82. 10.1186/1742-4690-9-82, 3484033, 23035819.
2. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010, 24(9):1243-1250.
3. Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans RM, Piscitelli SC. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005, 41(12):1787-1793. 10.1086/498310, 16288405.
4. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog 2011, 7(10):e1002286. 10.1371/journal.ppat.1002286, 3188520, 22007152.
5. Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 2009, 5(4):e1000395. 10.1371/journal.ppat.1000395, 2668697, 19390619.
6. Reynoso R, Wieser M, Ojeda D, Bönisch M, Kühnel H, Bolcic F, Quendler H, Grillari J, Grillari-Voglauer R, Quarleri J. HIV-1 induces telomerase activity in monocyte-derived macrophages-safeguarding one of its reservoirs?. J Virol 2012, 86(19):10327-10337. 10.1128/JVI.01495-12, 3457250, 22787205.
7. Gray L, Sterjovski J, Churchill M, Ellery P, Nasr N, Lewin SR, Crowe SM, Wesselingh SL, Cunningham AL, Gorry PR. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 2005, 337(2):384-398. 10.1016/j.virol.2005.04.034, 15916792.
8. Goodenow MM, Collman RG. HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol 2006, 80(5):965-972. 10.1189/jlb.0306148, 16923919.
9. Peters PJ, Sullivan WM, Duenas-Decamp MJ, Bhattacharya J, Ankghuambom C, Brown R, Luzuriaga K, Bell J, Simmonds P, Ball J, Clapham PR. Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. J Virol 2006, 80(13):6324-6332. 10.1128/JVI.02328-05, 1488974, 16775320.
10. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, Simmonds P, Clapham PR. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J Virol 2004, 78(13):6915-6926. 10.1128/JVI.78.13.6915-6926.2004, 421670, 15194768.
11. Musich T, Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, Ball JK, Luzuriaga K, Clapham PR. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. J Virol 2011, 85(5):2397-2405. 10.1128/JVI.02187-10, 3067776, 21159865.
12. Dunfee RL, Thomas ER, Gorry PR, Wang J, Taylor J, Kunstman K, Wolinsky SM, Gabuzda D. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A 2006, 103(41):15160-15165. 10.1073/pnas.0605513103, 1586182, 17015824.
13. Duenas-Decamp MJ, Peters PJ, Burton D, Clapham PR. Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J Virol 2009, 83(6):2575-2583. 10.1128/JVI.02133-08, 2648272, 19129457.
14. Keele BF. Identifying and characterizing recently transmitted viruses. Curr Opin HIV AIDS 2010, 5(4):327-334. 10.1097/COH.0b013e32833a0b9b, 2914479, 20543609.
15. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009, 206(6):1273-1289. 10.1084/jem.20090378, 2715054, 19487424.
16. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O, Mulenga J, Keele BF, Shaw GM, Hahn BH, Allen SA, Derdeyn CA, Hunter E. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009, 5(1):e1000274. 10.1371/journal.ppat.1000274, 2621345, 19165325.
17. Vermeire J, Vanbillemont G, Witkowski W, Verhasselt B. The Nef-infectivity enigma: mechanisms of enhanced lentiviral infection. Curr HIV Res 2011, 9(7):474-489. 10.2174/157016211798842099, 3355465, 22103831.
18. Lopez-Verges S, Camus G, Blot G, Beauvoir R, Benarous R, Berlioz-Torrent C. Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. Proc Natl Acad Sci U S A 2006, 103(40):14947-14952. 10.1073/pnas.0602941103, 1595456, 17003132.
19. Bhatia AK, Kaushik R, Campbell NA, Pontow SE, Ratner L. Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail. Virology 2009, 384(1):233-241. 10.1016/j.virol.2008.10.047, 2651518, 19059618.
20. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006, 80(23):11776-11790. 10.1128/JVI.01730-06, 1642599, 16971434.
21. Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog 2012, 8(5):e1002686. 10.1371/journal.ppat.1002686, 3364951, 22693444.
22. Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol 2011, 85(17):8514-8527. 10.1128/JVI.00736-11, 3165820, 21715507.
23. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, Hahn BH, Kappes JC. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 2012, 86(5):2715-2728. 10.1128/JVI.06157-11, 3302286, 22190722.
24. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Ségéral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474(7353):654-657. 10.1038/nature10117, 3595993, 21613998.
25. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474(7353):658-661. 10.1038/nature10195, 3179858, 21720370.
26. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012, 13(3):223-228. 10.1038/ni.2236, 3771401, 22327569.
27. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. Aids 2003, 17(13):1871-1879. 10.1097/00002030-200309050-00005, 12960819.
28. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A 1999, 96(9):5215-5220. 10.1073/pnas.96.9.5215, 21844, 10220446.
29. Duncan CJ, Sattentau QJ. Viral determinants of HIV-1 macrophage tropism. Viruses 2011, 3(11):2255-2279. 3230851, 22163344.
30. Johnston SH, Lobritz MA, Nguyen S, Lassen K, Delair S, Posta F, Bryson YJ, Arts EJ, Chou T, Lee B. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol 2009, 83(21):11016-11026. 10.1128/JVI.01242-09, 2772777, 19692480.
31. Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 2002, 20(11):1151-1154. 10.1038/nbt745, 12355096.
32. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self SG, Borrow P. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009, 83(8):3719-3733. 10.1128/JVI.01844-08, 2663284, 19176632.
33. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 2007, 110(13):4161-4164. 10.1182/blood-2007-06-097907, 17881634.
34. Tsang J, Tsang J, Chain BM, Miller RF, Webb BL, Barclay W, Towers GJ, Katz DR, Noursadeghi M. HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation. Aids 2009, 23(17):2255-2263. 10.1097/QAD.0b013e328331a4ce, 2873676, 19741482.
35. Sturdevant CB, Dow A, Jabara CB, Joseph SB, Schnell G, Takamune N, Mallewa M, Heyderman RS, Van Rie A, Swanstrom R. Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children. PLoS Pathog 2012, 8(12):e1003094. 10.1371/journal.ppat.1003094, 3531524, 23300446.
36. Goujon C, Arfi V, Pertel T, Luban J, Lienard J, Rigal D, Darlix JL, Cimarelli A. Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J Virol 2008, 82(24):12335-12345. 10.1128/JVI.01181-08, 2593360, 18829761.
37. Beloglazova N, Flick R, Tchigvintsev A, Brown G, Popovic A, Nocek B, Yakunin AF. Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction. J Biol Chem 2013, 288(12):8101-8110. 10.1074/jbc.M112.431148, 3605629, 23364794.
38. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, Kincer LP, Treurnicht FK, Arney L, Ojeda S, Zhang M, Keys J, Potter EL, Chu H, Moore P, Salazar MG, Iyer S, Jabara C, Kirchherr J, Mapanje C, Ngandu N, Seoighe C, Hoffman I, Gao F, Tang Y, Labranche C, Lee B, Saville A, Vermeulen M, Fiscus S, Morris L, Karim SA, Haynes BF, Shaw GM, Korber BT, Hahn BH, Cohen MS, Montefiori D, Williamson C, Swanstrom R, . CAPRISA Acute Infection Study and the Center for HIV-AIDS Vaccine Immunology Consortium Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol 2013, 87(13):7218-7233. 10.1128/JVI.03577-12, 3700278, 23616655, CAPRISA Acute Infection Study and the Center for HIV-AIDS Vaccine Immunology Consortium.
39. Potash MJ, Zeira M, Huang ZB, Pearce TE, Eden E, Gendelman HE, Volsky DJ. Virus-cell membrane fusion does not predict efficient infection of alveolar macrophages by human immunodeficiency virus type 1 (HIV-1). Virology 1992, 188(2):864-868. 10.1016/0042-6822(92)90543-X, 1585653.
40. Mori K, Ringler DJ, Desrosiers RC. Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J Virol 1993, 67(5):2807-2814. 237605, 7682627.
41. Arthos J, Rubbert A, Rabin RL, Cicala C, Machado E, Wildt K, Hanbach M, Steenbeke TD, Swofford R, Farber JM, Fauci AS. CCR5 signal transduction in macrophages by human immunodeficiency virus and simian immunodeficiency virus envelopes. J Virol 2000, 74(14):6418-6424. 10.1128/JVI.74.14.6418-6424.2000, 112149, 10864653.
42. Schmidtmayerova H, Alfano M, Nuovo G, Bukrinsky M. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J Virol 1998, 72(6):4633-4642. 109980, 9573226.
43. Schmitz C, Marchant D, Neil SJ, Aubin K, Reuter S, Dittmar MT, McKnight A. Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J Virol 2004, 78(4):2006-2016. 10.1128/JVI.78.4.2006-2016.2004, 369432, 14747565.
44. Marchant D, Neil SJ, Aubin K, Schmitz C, McKnight A. An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. J Virol 2005, 79(15):9410-9418. 10.1128/JVI.79.15.9410-9418.2005, 1181606, 16014904.
45. Pineda MJ, Orton BR, Overbaugh J. A TRIM5alpha-independent post-entry restriction to HIV-1 infection of macaque cells that is dependent on the path of entry. Virology 2007, 363(2):310-318. 10.1016/j.virol.2007.02.002, 2743720, 17350067.
46. Cicala C, Cicala C, Arthos J, Selig SM, Dennis G, Hosack DA, Van Ryk D, Spangler ML, Steenbeke TD, Khazanie P, Gupta N, Yang J, Daucher M, Lempicki RA, Fauci AS. HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci U S A 2002, 99(14):9380-9385. 10.1073/pnas.142287999, 123149, 12089333.
47. Kinter AL, Umscheid CA, Arthos J, Cicala C, Lin Y, Jackson R, Donoghue E, Ehler L, Adelsberger J, Rabin RL, Fauci AS. HIV envelope induces virus expression from resting CD4+ T cells isolated from HIV-infected individuals in the absence of markers of cellular activation or apoptosis. J Immunol 2003, 170(5):2449-2455.
48. Lin YL, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A 2002, 99(24):15590-15595. 10.1073/pnas.242134499, 137761, 12434015.
49. Bukrinskaya A, Brichacek B, Mann A, Stevenson M. Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J Exp Med 1998, 188(11):2113-2125. 10.1084/jem.188.11.2113, 2212381, 9841925.
50. Campbell EM, Nunez R, Hope TJ. Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J Virol 2004, 78(11):5745-5755. 10.1128/JVI.78.11.5745-5755.2004, 415815, 15140972.
51. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997, 71(8):5871-5877. 191842, 9223476.
52. Chazal N, Singer G, Aiken C, Hammarskjöld ML, Rekosh D. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol 2001, 75(8):4014-4018. 10.1128/JVI.75.8.4014-4018.2001, 114896, 11264394.
53. Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST. Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol 2000, 74(1):139-145. 10.1128/JVI.74.1.139-145.2000, 111522, 10590100.
54. Herbein G, Varin A. The macrophage in HIV-1 infection: from activation to deactivation?. Retrovirology 2010, 7:33. 10.1186/1742-4690-7-33, 2859752, 20380696.
55. Spenlehauer C, Gordon CA, Trkola A, Moore JP. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. Virology 2001, 280(2):292-300. 10.1006/viro.2000.0780, 11162843.
56. Bishop KN, Holmes RK, Malim MH. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 2006, 80(17):8450-8458. 10.1128/JVI.00839-06, 1563846, 16912295.
57. Clavel F, Hoggan MD, Willey RL, Strebel K, Martin MA, Repaske R. Genetic recombination of human immunodeficiency virus. J Virol 1989, 63(3):1455-1459. 247851, 2915387.